| Outcome | Cervical and/or endometrial Mg+ n (%) n = 88 | Cervical and/or endometrial Mg− n (%) n = 498 | Adjusted RR¶ (95% CI) | Endometrial Mg+ n (%) n = 50 | Endometrial Mg− n (%) n = 561 | Adjusted RR¶ (95% CI) | |
| Treatment failure* | 8 (40.0) | 26 (17.5) | 2.6 (0.8 to 8.9) | 6 (50.0) | 30 (18.5) | 4.6 (1.1 to 20.1) | |
| Endometritis at 30 days† | 25 (56.8) | 119 (39.0) | 1.9 (0.9 to 3.9) | 19 (70.4) | 131 (39.2) | 4.0 (1.5 to 10.9) | |
| Incident endometritis‡ | 6 (24.0) | 35 (15.8) | 1.5 (0.4 to 5.0) | 5 (38.5) | 37 (15.4) | 5.0 (1.2 to 20.6) | |
| Persistent endometritis§ | 17 (47.2) | 73 (28.2) | 2.1 (1.0 to 4.6) | 13 (61.9) | 82 (28.8) | 4.1 (1.4 to 11.9) | |
*Treatment failure is defined as both endometritis and pelvic pain present at the 30 day clinic visit; †All women categorised as having endometritis at the 30 day clinic visit; ‡includes women without endometritis at baseline who are categorised as having endometritis at the 30 day clinic visit; §includes women who are categorised as having endometritis at both baseline and 30 days; ¶Adjusted for age and race, self reported partner treatment and intercourse between baseline and the 30 day clinic visit.